Your institution may have access to this item. Find your institution then sign in to continue.
Title
Orexin receptor agonist improves outcomes in narcolepsy, but with liver effects.
Abstract
The article focuses on a Phase 2 trial evaluating the efficacy and safety of TAK-994, an orexin 2 receptor agonist, for treating narcolepsy type 1, including the positive impact on sleep latency and daytime sleepiness but also the early termination of the study due to hepatotoxic effects.